Eli Lilly Gets CDSCO Nod To Study Anti-diabetic Dulaglutide

Published On 2022-11-12 12:30 GMT | Update On 2022-11-12 12:30 GMT

New Delhi: Pharmaceutical major, Eli Lilly has got the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) approval to study the Phase IV study of anti-diabetic drug Dulaglutide as per the study protocol.

This came after the firm presented the protocol for conduct of Phase IV study titled "A 24-week multicenter, open-label, single-arm study to evaluate safety in patients with type 2 diabetes mellitus in India treated with Dulaglutide". Protocol no.H9X-IN-GBGR, H9X-IN-GBGR(a)dated 16 Sep 2022.

Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events.

Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.

At the recent SEC meeting for Endocrinology and Metabolism held on 19th and 20th October 2022, the expert panel reviewed the protocol presented by the firm to conduct Phase IV study of the anti-diabetic drug Dulaglutide in order to evaluate safety in patients with type 2 diabetes mellitus.

After detailed deliberation, the committee recommended the grant of permission to conduct the study as per presented protocol.:

Also Read:Dr. Reddy proposal to market antidiabetic FDC of Imeglimin and Vildagliptin rejected by CDSCO Panel

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Eli Lilly Gets CDSCO Nod To Study Anti-diabetic Dulaglutide

Similar News

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII